A meta-analysis indicates that sentinel node biopsy significantly reduces mortality and recurrence risk in melanoma patients compared to those who do not undergo the procedure.
A recent meta-analysis has revealed that melanoma patients who undergo sentinel node biopsy (SNB) experience a significantly lower risk of mortality and recurrence compared to those who do not receive this procedure. These outcomes align with findings from the only existing randomized controlled trial and remained consistent across various sensitivity analyses. This reinforces the conclusion that SNB provides genuine benefits regarding survival and reducing recurrence rates in melanoma cases.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.
Personalise this feed
Your specialty. Your sources. Your digest.
All set up in under 2 minutes.